Table 3.
Predictors of Absence of Dysplasia or Adenocarcinoma at 3-Month Follow-Up Evaluation on Univariate Analyses
| Variable (N = data available on) | Groups | Proportion of responders | OR (95% CI) |
|---|---|---|---|
| Age, y (n = 126) | ≤67 y | 40% (23/57) | 1.00 (0.97–1.04) |
| >67 y | 39% (27/69) | ||
| Male sex (n = 126) | Yes | 39% (44/113) | 1.34 (0.42–4.26) |
| No | 46% (6/13) | ||
| EMR before PDT (n = 126) | Yes | 37% (40/109) | 0.41 (0.14–1.15) |
| No | 59% (10/17) | ||
| BE segment length (n = 126) | ≤5 cm | 50% (40/79) | 0.77 (0.67–0.88) |
| >5 cm | 21% (10/47) | ||
| PDT (n = 126) | Yes | 54% (38/71) | 4.13 (1.87–9.11) |
| No | 22% (12/55) | ||
| P16 loss (n = 126) | Yes | 15% (6/41) | 0.32 (0.14–0.75) |
| No | 50% (36/72) | ||
| P53 loss (n = 120) | Yes | 21% (7/34) | 0.30 (0.12–0.76) |
| No | 47% (40/86) | ||
| C-MYC (8q24) gain (n = 125) | Yes | 41% (20/49) | 0.91 (0.44–1.86) |
| No | 39% (30/77) | ||
| HER2-NEU (17q) gain (n = 124) | Yes | 28% (5/18) | 0.50 (0.21–1.20) |
| No | 42% (45/108) | ||
| 20q13 gain (n = 125) | Yes | 33% (9/27) | 0.68 (0.32–1.45) |
| No | 41% (41/99) | ||
| Multiple gains (n = 125) | Yes | 33% (16/49) | 0.70 (0.33–1.49) |
| No | 44% (34/77) | ||
| Multiple gains or any gains (n = 125) | Yes | 33% (25/75) | 0.84 (0.41–1.72) |
| No | 50% (25/50) |